Treatment of 1036 patients from rural (29.7 %) and urban (70.3 %) origin with norethisterone enanthate, a long term progestogen used as a contraceptive, is reported. The contraceptive effect is high, failure rate being 1.58 per 100 woman-years. Protection is extended far 12 weeks and the effect is reversible. Disturbances were present in 35.4% of the cycles, specially when treatment was started in postpartum amenorrheic, lactating women. The most frequent alteration was poli-hypermenorrhea. Intermenstrual spotting or bleeding tends to decrease after the initial months of treatment. The low incidence in inhibition of lactation as well as in general side effects, and its marked acceptability among women of low social-economic level are highly positive facts far this new contraceptive measure.

Several parameters were studied to clarity the mechanisms of action of two long-acting injectable contraceptive progrstins: 17-a-19-hydroxynorprogesterone caproate (which contraceptive effectiveness clinically lasts at least 8 weeks) and 19-norethindrone enanthate (effectiveness over 12 weeks). The "classic" theory of ovulation-inhibition was found uncovincing. In 14 ovarian biopsies of patients under treatment, taken in the second phase of the cycle, ovulation was evident in 11 of them by presence of corpora lutea. 245 endometrial biopsies showed that exogenus gestagen effect lasts only three weeks; after this period most endometria could be correlated with the cycle-day on which they were taken: 2/3 of these suggested biphasic cycles. Evaluation of 240 colpocytograms also confirmed endogenous cyclic activity. In order to explain the long-acting contraceptive effectiveness, cervical muc...

Several parameters were studied to clarity the mechanisms of action of two long-acting injectable contraceptive progrstins: 17-a-19-hydroxynorprogesterone caproate (which contraceptive effectiveness clinically lasts at least 8 weeks) and 19-norethindrone enanthate (effectiveness over 12 weeks). The "classic" theory of ovulation-inhibition was found uncovincing. In 14 ovarian biopsies of patients under treatment, taken in the second phase of the cycle, ovulation was evident in 11 of them by presence of corpora lutea. 245 endometrial biopsies showed that exogenus gestagen effect lasts only three weeks; after this period most endometria could be correlated with the cycle-day on which they were taken: 2/3 of these suggested biphasic cycles. Evaluation of 240 colpocytograms also confirmed endogenous cyclic activity. In order to explain the long-acting contraceptive effectiveness, cervical muc...

The authors have studied the contraceptive effect of 17-Alpha Hydroxi-19-Norprogesterona Capronate (SN - 582) in 21 normal women; the effect is present during 6-8 weeks after the inyection of 200 mg. During this time menstrual irregularities as spotting and amenorrhea were observed, but their incidence was lower than those produced by the norethisterone enanthate (SN - 393).

Hormone Replacement Therapy - Specific effects of different hormones, hormone pray, transdermal hormone therapy, hormone - Injectable.

Se evalúa 639 adolescentes que acudieron al Hospital San Bartolomé y al Instituto San Marcelino entre los años 1977 y 1982, constituyendo el 4,22% del total de usuarias. El 12.67% de los casos tenía menos de 16 años de edad; sólo el 5.45 o/o no tuvo embarazo previo. La mayoría de los casos -64.32%-prefirieron el D.I.U. como método y, en segundo lugar- 18.16% -, la tableta anticonceptiva. En 13.93% se administró progestinas de depósito.  El método más eficaz y con menor porcentaje de fallas -0.74/100 años mujer- fue la tableta anticonceptiva, contra el 3.6 de fallas con el D.I.U. Se observó más complicaciones con el D.I.U -28%- y con la amenaza adicional de complicaciones potenciales. 

Se evalúa 639 adolescentes que acudieron al Hospital San Bartolomé y al Instituto San Marcelino entre los años 1977 y 1982, constituyendo el 4,22% del total de usuarias. El 12.67% de los casos tenía menos de 16 años de edad; sólo el 5.45 o/o no tuvo embarazo previo. La mayoría de los casos -64.32%-prefirieron el D.I.U. como método y, en segundo lugar- 18.16% -, la tableta anticonceptiva. En 13.93% se administró progestinas de depósito.  El método más eficaz y con menor porcentaje de fallas -0.74/100 años mujer- fue la tableta anticonceptiva, contra el 3.6 de fallas con el D.I.U. Se observó más complicaciones con el D.I.U -28%- y con la amenaza adicional de complicaciones potenciales.